Q1FY25 Quarterly Result Announced for Innova Captab Ltd.
Pharmaceuticals company Innova Captab announced Q1FY25 results:
- Revenue from operation is Rs 294.3 crore in Q1FY25 as against Rs 233.2 crore of Q1FY24 registering a growth of 26%.
- The Company’s EBITDA stood at Rs 44.3 crore in Q1FY25 against Rs 32.4 crore of Q1FY24 registering a growth of 37%.
- Profit After Tax (PAT) stood at Rs 29.5 crore in Q1FY25 against Rs 17.6 crore of Q1FY24 registering a growth of 68%
Commenting on the results, Vinay Lohariwala, Managing Director, - Innova Captab said, For Q1FY25, we reported a total income of Rs 296 crores, a 27% growth compared to same quarter previous year. All business areas are experiencing healthy growth and are expected to maintain this momentum in the coming quarters.
Over the past 3-4 years, our revenue has grown at a robust growth rate. With the new Jammu facility, we are optimistic about sustaining this growth trajectory over the next few years.
As a company, we remain committed to driving sustainable growth by exploring new opportunities and focusing on value-added products. The Indian pharmaceutical sector is poised for significant growth in the mid to long term, with both domestic and global MNCs are increasingly seeking reliable and sustainable suppliers like us.
The foundation of Innova is their in-house research and development which helps to focus on building complex product portfolio. As a major CDMO player, Innova caters to India’s top 14 out of 15 pharmaceuticals companies and have license to manufacture products through four state of the art manufacturing facilities at Baddi - Himachal Pradesh, Dehradun - Uttarakhand and at Taloja - Maharashtra while maintaining WHO-GMP, EU-GMP, UK-MHRA and other major registrations with these facilities.
By Q2FY25, the upcoming greenfield plant in Jammu is expected to be commercialized. This facility will have four production blocks: cephalosporin, penicillin, penum and BFS and will manufacture oral solid dosages, dry powder injections, dry syrup, BFS, Large Volume Parenterals and respiratory respule products.